1. Ranibizumab cost effective for common cause of vision loss.
- Subjects
- *
COST analysis , *COST effectiveness , *DRUG prices , *EDEMA , *METABOLIC disorder treatment , *RETINAL vein , *LASER coagulation , *QUALITY-adjusted life years , *THERAPEUTICS , *DISEASES - Abstract
The article discusses three studies on the cost effectiveness of ranizumab for macular oedema secondary to branch or central retinal vein occlusion (BRVO or CRVO) treatment when compared to laser photocoagulation therapy. The study in Great Britain shown that ranibizumab has incremental cost-effectiveness ratios (ICERs) of £15 710 per quality-adjusted life year (QALY). It mentions that in Canada ICERs are at $Can36 725 per QALY. Meanwhile, in the U.S. ICERs are at $U.S.19 270 per QALY.
- Published
- 2012
- Full Text
- View/download PDF